Zentalis Pharmaceuticals Inc (ZNTL) オプション

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

ZNTL.......................................https://stockcharts.com/h-sc/ui?s=ZNTL&p=W&b=5&g=0&id=p86431144783

ZNTL under $4

We managed to get a new 26 week high and a reset around 46 bucks, will be interesting to see where it goes next, chartwise it's up, imo of course, ANT

Added some 46's , nice chart reset, ANT

55.12~~ looks like this puppy is on it's way for a new 52 week high, my target here is 100 bucks because of the very promising pipeline , fyi imo ANT

NEW YORK and SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Ahmed Samatar, Ph.D., Senior Vice President of Oncology Research at Zentalis, will present preclinical data on ZN-c5 at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting II taking place June 22-24th.

The preclinical data demonstrated that ZN-c5, the Company’s oral selective estrogen receptor degrader (SERD) product candidate, had antitumor activity in human tumor breast cancer xenograft models. ZN-c5 also displayed excellent oral bioavailability across several preclinical species. ZN-c5 is currently being evaluated in a Phase 1/2 clinical trial in patients with ER+/HER2- advanced or metastatic breast cancer both as a single agent and in combination studies.

NEW YORK and SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals (ZNTL), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30 p.m. ET.
fyi ANT

New 52 week high at 52.09, i luv it, ANT

Cash Position: As of March 31, 2020, Zentalis had cash and cash equivalents of $63.7 million. We expect that the Company’s existing cash and cash equivalents, together with the net proceeds of $172.4 million from the IPO, will enable the Company to fund its operating expenses and capital expenditure requirements into 2022.
fyi ANT

Chart is pretty fresh here, anyway, i see a trendline curlin' up already (10ma on the daily at 35.9), fyi ANT

promisin' co, interestin' pipeline, touched new 52 week high today (42.83), enormous spread every now and then, fyi ANT

ZNTL opens @ 25.20 >

Zentalis Pharma Upsized IPO Prices at High End of Range >ZNTL
6:08 am ET April 3, 2020 (Dow Jones) Print
By Colin Kellaher

Zentalis Pharmaceuticals Inc. said its upsized initial public offering of 9.18 million shares was priced at $18 each, the high end of the expected range.

The New York clinical-stage cancer biopharmaceutical company earlier this week said it expected to sell 7.65 million shares at $16 to $18 apiece.

Zentalis said it expects gross proceeds of $165.2 million from the IPO, adding that it has granted the underwriters an option to buy up to 1.38 million additional shares.

Zentalis previously said it will use proceeds from the offering to advance the development of its drug candidates.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 03, 2020 06:08 ET (10:08 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Zentalis Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.